Erleada Global Market Report 2025

Description

Erleada is a prescription medication used to treat specific forms of prostate cancer, including non-metastatic and metastatic castration-resistant prostate cancer. It functions by blocking androgen receptors, helping slow the growth and spread of cancer cells that depend on male hormones. It is administered orally and is often combined with hormone therapy to improve treatment effectiveness.

The main types in the Erleada market include branded and generic products. Branded Erleada refers to the original, patented formulation of apalutamide developed and marketed by Janssen Pharmaceuticals, created to inhibit androgen receptor signaling in prostate cancer cells. It is primarily used to treat prostate cancer by delaying disease progression and improving overall survival outcomes for men with advanced or treatment-resistant forms of the condition. Key indications or disease stages include metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-sensitive prostate cancer (mCSPC). Distribution channels include hospital pharmacies, retail pharmacies, and others. The major patient groups or end users include hospitals, specialty clinics or oncology centers, and home care or outpatient settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The erleada market research report is one of a series of new reports from The Business Research Company that provides erleada market statistics, including the erleada industry global market size, regional shares, competitors with the erleada market share, detailed erleada market segments, market trends, and opportunities, and any further data you may need to thrive in the erleada industry. This erleada market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The erleada market size has grown strongly in recent years. It will grow from $2.76 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to the increasing incidence of hormone-resistant prostate cancer, rising use of androgen deprivation therapies, growing investment in oncology research, expanding access to advanced cancer care, and increasing physician preference for oral prostate cancer medications.

The erleada market size is expected to see strong growth in the next few years. It will grow to $4.31 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising demand for minimally invasive cancer treatments, increasing adoption of next-generation anti-androgens, growing healthcare expenditure in oncology, expanding availability of precision medicine programs, and greater awareness of the survival benefits associated with early treatment. Major trends expected in the forecast period include technological advancements in clinical trial design, innovations in androgen receptor-targeting mechanisms, the development of digital health tools for cancer management, ongoing research and development in radioligand and combination therapies, and advancements in artificial intelligence-based cancer diagnostics.

The rising prostate cancer prevalence is expected to propel the growth of the Erleada market going forward. Prostate cancer refers to a malignant tumor that develops in the prostate gland, a part of the male reproductive system. The rising prevalence of prostate cancer is driven by increasing life expectancy, as older age significantly raises the likelihood of developing this disease. Erleada helps treat prostate cancer by blocking androgen receptors, preventing male hormones from stimulating the growth and spread of cancer cells. For instance, according to data published by the Australian Government in November 2025, around 28,868 new prostate cancer cases were reported, accounting for about 30% of all new male cancer diagnoses, with an estimated 3,975 deaths. Therefore, the rising prostate cancer prevalence is driving the growth of the Erleada market.

The increasing adoption of advanced androgen receptor inhibitors is expected to propel the growth of the Erleada market going forward. Advanced androgen receptor inhibitors refer to a new class of prostate cancer drugs that more effectively block androgen receptor signaling, slowing cancer progression and improving patient survival rates. The increasing adoption of these advanced therapies is driven by rising clinical success rates, favorable treatment outcomes, and growing healthcare awareness. Erleada, as one of the leading next-generation androgen receptor inhibitors, offers enhanced efficacy and safety, making it a preferred choice among oncologists. For instance, according to clinical data published in the Journal of Clinical Oncology, treatment with apalutamide (Erleada) demonstrated a 72% reduction in the risk of metastasis or death compared to placebo in patients with non-metastatic castration-resistant prostate cancer. Therefore, the increasing adoption of advanced androgen receptor inhibitors is driving the growth of the Erleada market.

Major companies operating in the Erleada market are focusing on innovation, such as reduced pill burden, to enhance patient convenience, improve treatment adherence, and provide more personalized therapy options for prostate cancer patients. Reduced pill burden refers to lowering the number of pills a patient needs to take by combining medications or reducing dosing frequency. It helps improve treatment adherence and overall patient convenience. For instance, in April 2023, Johnson & Johnson, a U.S.-based company that develops, manufactures, and sells pharmaceuticals for various diseases such as oncology, immunology, and neuroscience, as well as medical devices for surgery, orthopedics, and vision, announced the availability of an additional tablet strength of Erleada (apalutamide) in the United States. The introduction of the 240 mg tablet provides the first and only option for a once-daily, single-tablet androgen receptor inhibitor approved for the treatment of patients with non-metastatic castration-resistant prostate cancer and for the treatment of patients with metastatic castration-sensitive prostate cancer.

Major companies operating in the erleada market are Johnson & Johnson

North America was the largest region in the erleada market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in erleada report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the erleada market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The erleada market consists of sales of erleada 60 mg tablets, and erleada 240 mg tablets. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Erleada Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on erleada market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for erleada ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The erleada market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Branded; Generic
2) By Indication Or Disease Stage: Metastatic Castration-Resistant Prostate Cancer (mCRPC); Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC); Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
4) By Patient Type Or End User: Hospitals; Specialty Clinics Or Oncology Centers; Home Care Or Outpatient Settings
Subsegments:
1) By Branded: Innovator Brand; Co-Branded Formulation; Licensed Brand Extension
2) By Generic: Unbranded Generic; Authorized Generic; Parallel Import Generic
Companies Mentioned: Johnson & Johnson
Countries:

Product Code: r40003

1. Executive Summary

2. Erleada Market Characteristics

3. Erleada Market Trends And Strategies

4. Erleada Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Erleada Growth Analysis And Strategic Analysis Framework

5.1. Global Erleada PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Erleada Market Growth Rate Analysis
5.4. Global Erleada Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Erleada Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Erleada Total Addressable Market (TAM)

6. Erleada Market Segmentation

6.1. Global Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded
Generic
6.2. Global Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
6.3. Global Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
6.4. Global Erleada Market, Segmentation By Patient Type Or End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics Or Oncology Centers
Home Care Or Outpatient Settings
6.5. Global Erleada Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Innovator Brand
Co-Branded Formulation
Licensed Brand Extension
6.6. Global Erleada Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Unbranded Generic
Authorized Generic
Parallel Import Generic

7. Erleada Market Regional And Country Analysis

7.1. Global Erleada Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Erleada Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Erleada Market

8.1. Asia-Pacific Erleada Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Erleada Market

9.1. China Erleada Market Overview
9.2. China Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Erleada Market

10.1. India Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Erleada Market

11.1. Japan Erleada Market Overview
11.2. Japan Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Erleada Market

12.1. Australia Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Erleada Market

13.1. Indonesia Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Erleada Market

14.1. South Korea Erleada Market Overview
14.2. South Korea Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Erleada Market

15.1. Western Europe Erleada Market Overview
15.2. Western Europe Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Erleada Market

16.1. UK Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Erleada Market

17.1. Germany Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Erleada Market

18.1. France Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Erleada Market

19.1. Italy Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Erleada Market

20.1. Spain Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Erleada Market

21.1. Eastern Europe Erleada Market Overview
21.2. Eastern Europe Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Erleada Market

22.1. Russia Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Erleada Market

23.1. North America Erleada Market Overview
23.2. North America Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Erleada Market

24.1. USA Erleada Market Overview
24.2. USA Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Erleada Market

25.1. Canada Erleada Market Overview
25.2. Canada Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Erleada Market

26.1. South America Erleada Market Overview
26.2. South America Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Erleada Market

27.1. Brazil Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Erleada Market

28.1. Middle East Erleada Market Overview
28.2. Middle East Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Erleada Market

29.1. Africa Erleada Market Overview
29.2. Africa Erleada Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Erleada Market, Segmentation By Indication Or Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Erleada Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Erleada Market Competitive Landscape And Company Profiles

30.1. Erleada Market Competitive Landscape
30.2. Erleada Market Company Profiles
- 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

332. Global Erleada Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Erleada Market

34. Recent Developments In The Erleada Market

35. Erleada Market High Potential Countries, Segments and Strategies

35.1 Erleada Market In 2029 - Countries Offering Most New Opportunities
35.2 Erleada Market In 2029 - Segments Offering Most New Opportunities
35.3 Erleada Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer